Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 华兰生物工程股份有限公司是一家主要从事血液制品、菌疫苗的生产和销售的公司.公司的主要产品包括人血白蛋白、静注人免疫球蛋白(PH4)、人凝血酶原复合物、人凝血因子Ⅷ等.公司目前生产规模、市场占有率均居行业前列,成为血液制品、疫苗产品行业的龙头企业.1998年公司是首家通过了血液制品行业的GMP认证,为国家定点大型生物制品生产企业,在全国同行业企业中处于领先地位.公司先后承担多项国家、省、市级科技攻关项目,其中外科用冻干人纤维蛋白胶被列入国家863项目.公司在2009年发生的甲型H1N1流感疫情中依靠公司的科研实力在全球率先研制出甲型H1N1流感疫苗,公司甲流疫苗临床研究报告刊登于世界顶尖医学杂志《新英格兰医学杂志》,标志着中国疫苗得到了世界的认可,开创了中国疫苗的先河。
Main Business 血液制品业务、疫苗制品、创新药和生物类似药研发、生产三类业务
Legal Representative 安康
Top Executives
董事长：安康
董事：范蓓,安文珏,安文琪,张宝献,潘若文
独立董事：苏志国,刘万丽,王云龙
Top 5 Shareholder
Shareholder name Nature Holding Date
安康限售股+流通A股17.92%30/09/2024
重庆市晟康生物科技开发有限公司流通A股15.01%30/09/2024
香港科康有限公司流通A股13.12%30/09/2024
中国证券金融股份有限公司流通A股2.97%30/09/2024
香港中央结算有限公司流通A股2.17%30/09/2024
Company Secretary 谢军民
Solicitors 安徽承义律师事务所
Auditors 天健华证中洲(北京)会计师事务所有限公司
Tel No 0373-3559989
Fax No 0373-3559991
Website www.hualanbio.com
Email hualan@hualanbio.com
Company Address
Register: 河南省新乡市华兰大道甲1号
Office: 河南省新乡市华兰大道甲1号
Listing Date 25/06/2004
Shares Capital
Shares Capital: 1,828,780,926
Total A Share: 1,828,780,926
Listed A Share: 1,573,911,894
Non-tradable A Share: 254,869,032
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.812
DPS(RMB)* ¥ 0.300
NBV Per Share(RMB)* ¥ 6.211
Market Capitalization(RMB) 26.662B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.